Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment

Background Systemic cancer spread is preceded by the establishment of a permissive microenvironment in the target tissue of metastasis - the premetastatic niche. As crucial players in establishment of the pre-metastatic niche, myeloid derived suppressor cells (MDSC) release S100A8/A9, an exosomal protein that contributes to metastasis, angiogenesis, and immune suppression. We report the application of antibody-based single-photon emission computed tomography (SPECT) for detection of S100A8/A9 in vivo as an imaging marker for pre-metastatic tissue priming. Methods A syngeneic model system for invasive breast cancer with (4T1.2) or without (67NR) the tendency to form lung metastasis was established in BALB/c mice. A SPECT-probe has been generated and tested for visualization of S100A9 release. Tumor-associated changes in numbers and fuction of immune cells in pre-metastatic tissue were evaluated by flow cytometry and confocal microscopy. Results S100A8/A9 imaging reflected MDSC abundance and the establishment of an immunosuppressive environment in pre-metastatic lung tissue (activity 4T1.2 vs. healthy control: 0.95 vs. 0.45 %ID; p<0.001). The S100A8/A9 imaging signal in the pre-metastatic lung correlated with the subsequent metastatic tumor burden in the same organ (r2=0.788; p<0.0001). CCL2 blockade and the consecutive inhibition of premetastatic niche establishment was clearly depicted by S100A9-SPECT (lung activity untreated vs. treated: 2 vs, 1.4 %ID). Conclusion We report S100A8/A9 as a potent imaging biomarker for tumor-mediated immune remodeling with potential applications in basic research and clinical oncology.

[1]  H. Rui,et al.  Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  J. Bruneau,et al.  Functional analysis of NK cell subsets activated by 721.221 and K562 HLA‐null cells , 2015, Journal of leukocyte biology.

[3]  W. Heindel,et al.  Optical In Vivo Imaging of the Alarmin S100A9 in Tumor Lesions Allows for Estimation of the Individual Malignant Potential by Evaluation of Tumor–Host Cell Interaction , 2015, The Journal of Nuclear Medicine.

[4]  M. Shurin,et al.  Myeloid regulatory cells in tumor spreading and metastasis. , 2015, Immunobiology.

[5]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[6]  C. Bremer,et al.  Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity , 2014, Nature Communications.

[7]  F. Bestvater,et al.  Impact of S100A8/A9 Expression on Prostate Cancer Progression In Vitro and In Vivo , 2014, Journal of cellular physiology.

[8]  Meghan C. Burke,et al.  Exosomes from myeloid-derived suppressor cells carry biologically active proteins. , 2014, Journal of proteome research.

[9]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[10]  S. Lang,et al.  The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? , 2013, Seminars in cancer biology.

[11]  K. Pienta,et al.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer , 2013, Investigational New Drugs.

[12]  H. Aburatani,et al.  Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci , 2013, Nature Communications.

[13]  J. Serody,et al.  Circulating Fibrocytes Prepare the Lung for Cancer Metastasis by Recruiting Ly-6C+ Monocytes Via CCL2 , 2013, The Journal of Immunology.

[14]  Pieter Wesseling,et al.  The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells , 2013, Immunology.

[15]  K. Lam,et al.  Molecular Imaging of Very Late Antigen–4 (α4β1 Integrin) in the Premetastatic Niche , 2012, The Journal of Nuclear Medicine.

[16]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[17]  A. Clayton.  Cancer cells use exosomes as tools to manipulate immunity and the microenvironment , 2012, Oncoimmunology.

[18]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[19]  M. Duffy,et al.  The role of S100 genes in breast cancer progression , 2011, Tumor Biology.

[20]  Roy M. Williams,et al.  S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression , 2011, Molecular Cancer Research.

[21]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[22]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[23]  S. Briest,et al.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. , 2009, Cancer research.

[24]  S. Mocellin,et al.  IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1 , 2009, The Journal of Immunology.

[25]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[26]  Hiroyuki Aburatani,et al.  The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.

[27]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[28]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[29]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[30]  J. Kappes,et al.  Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. , 2007, Blood.

[31]  A. Mantovani,et al.  Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6 , 2007, Proceedings of the National Academy of Sciences.

[32]  S. Rafii,et al.  Preparing the "soil": the premetastatic niche. , 2006, Cancer research.

[33]  Hiroyuki Aburatani,et al.  Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis , 2006, Nature Cell Biology.

[34]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[35]  M. Smyth,et al.  CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1 , 2006, The Journal of Immunology.

[36]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[37]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[38]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[39]  W. Nacken,et al.  S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity , 2003, Microscopy research and technique.

[40]  T. Martin,et al.  A novel orthotopic model of breast cancer metastasis to bone , 1999, Clinical & Experimental Metastasis.

[41]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[42]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[43]  M. Mandalà,et al.  Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. , 2014, Critical reviews in oncology/hematology.

[44]  S. Mather,et al.  Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.